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BACKGROUND & AIMS: Patients with perianal fistulizing
Crohn’s disease have a poor prognosis because these lesions
do not heal well. We evaluated the effects of local administra-
tion of bone marrowderived mesenchymal stromal cells
(MSCs) to these patients from healthy donors in a double-blind,
placebo-controlled study. METHODS: Twenty-one patients
with refractory perianal fistulizing Crohn’s disease were
randomly assigned to groups given injections of 1  107 (n ¼ 5,
group 1), 3  107 (n ¼ 5, group 2), or 9  107 (n ¼ 5, group 3)
MSCs, or placebo (solution with no cells, n ¼ 6), into the wall of
curettaged fistula, around the trimmed and closed internal
opening. The primary outcome, fistula healing, was determined
by physical examination 6, 12, and 24 weeks later; healing
was defined as absence of discharge and <2 cm of fluid
collection—the latter determined by magnetic resonance im-
aging at week 12. All procedures were performed at Leiden
University Medical Center, The Netherlands, from June 2012
through July 2014. RESULTS: No adverse events were associ-
ated with local injection of any dose of MSCs. Healing at week 6
was observed in 3 patients in group 1 (60.0%), 4 patients in
group 2 (80.0%), and 1 patient in group 3 (20.0%), vs 1 patient
in the placebo group (16.7%) (P ¼ .08 for group 2 vs placebo).
At week 12, healing was observed in 2 patients in group 1
(40.0%), 4 patients in group 2 (80.0%), and 1 patient in
group 3 (20.0%), vs 2 patients in the placebo group (33.3%);
these effects were maintained until week 24 and even
increased to 4 (80.0%) in group 1. At week six, 4 of 9 individual
fistulas had healed in group 1 (44.4%), 6 of 7 had healed in
group 2 (85.7%), and 2 of 7 had healed in group 3 (28.6%) vs 2
of 9 (22.2%) in the placebo group (P ¼ .04 for group 2 vs
placebo). At week twelve, 3 of 9 individual fistulas had healed
in group 1 (33.3%), 6 of 7 had healed in group 2 (85.7%), 2 of 7
had healed in group 3 (28.6%), and 3 of 9 had healed in the
placebo group (33.3%). These effects were stable through week
24 and even increased to 6 of 9 (66.7%) in group 1 (P ¼ .06
group 2 vs placebo, weeks 12 and 24). CONCLUSIONS: Local
administration of allogeneic MSCs was not associated withsevere adverse events in patients with perianal fistulizing
Crohn’s disease. Injection of 3  107 MSCs appeared to pro-
mote healing of perianal fistulas. ClinicalTrials.gov ID
NCT01144962.Keywords: Cell Therapy; Perianal Fistulas; Treatment;
Inflammatory Bowel Disease.
erianal fistulizing Crohn’s disease (CD) remains aPsignificant clinical challenge greatly affecting pa-
tients’ quality of life due to pain, discharge, and abscess
formation.1 At least 23%26% of CD patients develop
perianal fistulas within 20 years after diagnosis.2,3
Achieving complete fistula healing is often a long process
accompanied by multiple relapses. Patients frequently fail to
respond to current medical options, including antibiotics,
immunosuppressive agents, and anti-tumor necrosis factor
(TNF) biologicals.46 To prevent abscess formation, surgical
placement of noncutting setons is often required. In more
severe cases, fecal diversion is needed to attenuate perianal
disease.7 The ultimate treatment goal is complete fistula
healing without sphincter damage. Unfortunately, despite
the best available therapies, durable remission rates of
complex perianal fistulas remain low at 37.0%.8
An emerging therapeutic approach is the use of mesen-
chymal stromal cells (MSCs). These are nonhematopoietic
multipotent cells able to down-regulate immune responses
and promote tissue healing. It has been reported that human
MSCs are able to inhibit generation of dendritic cells from
monocytes, are capable of down-regulating expression of





ATpresentation and costimulatory molecules on mature den-
dritic cells preventing T-cell activation, and promote the
generation of regulatory T cells.914 In addition, MSCs
participate in tissue-repair processes, providing a strong
rationale for the use of these cells as a treatment for perianal
fistulizing CD. Recently, phase I and II clinical trials have
shown promising results on the healing rates of perianal
fistulas.1520 Locally injected MSCs demonstrated 69%
82% fistula healing.1618,20 MSCs used in these trials were
predominantly harvested from autologous adipose tissue
and were reported to be a safe and feasible option. However,
autologous MSCs are not immediately available upon request
because isolation and expansion of MSCs to sufficient
numbers of cells requires weeks, resulting in treatment
delay. In addition, the possibility of disease-related effects on
autologous MSCs must be taken into account. Therefore, we
used allogeneic MSCs derived from bone marrow aspirates
of healthy donors. Until now, no similar placebo-controlled
trials have been performed. We report the results of a ran-
domized, double-blind, placebo-controlled, dose-escalating
clinical trial evaluating the safety and efficacy of allogeneic
bone marrowderived MSCs in addition to surgical treat-
ment of refractory perianal fistulizing CD.Methods
Patient Selection and Study Design
Eligible patients were men and women of at least 18 years
of age with actively draining perianal fistulizing CD refractory
to conventional therapies, meaning that at some time during
the perianal fistula disease course, the patient must have
received anti-TNF agents and, in addition, antibiotics, steroids,
thiopurines, methotrexate, surgery, or combinations thereof
that did not result in an adequate treatment response. Eligible
patients had to have 12 internal openings and 13 fistula
tracts. Additional criteria for inclusion were diagnosis of CD at
least 3 months before enrollment, CD Activity Index (CDAI)
score of <250 at screening and baseline, stable dose of current
drugs (mesalamine and steroids 4 weeks; immunosuppres-
sive drugs 8 weeks; anti-TNF agents 8 weeks), which were
continued during the entire study period. Patients were not
allowed to use antibiotics after inclusion in the trial. In addition,
patients were not eligible if there was need for immediate
surgery (obstruction, strictures, or abscesses); pregnancy;
breastfeeding; or when they did not use adequate contracep-
tion. Additional exclusion criteria were evidence of any infec-
tion needing antibiotic treatment; rectovaginal fistulas;
complex perianal fistulas with >2 internal openings; evidence
of acute perianal infection; and presence of an anal or rectal
stricture hindering the surgeon to adequately perform the
intervention; active luminal disease; renal or hepatic failure;
use of any investigational drug within 1 month before screening
or within 5 half-lives of the investigational agent (whichever is
longer); not able or willing to undergo magnetic resonance
imaging (MRI); change in concomitant medication; documented
human immunodeficiency virus infection; active hepatitis B, C,
or tuberculosis; an opportunistic infection within 6 months
before screening or a serious infection in the previous
3 months; malignancy within the past 5 years; or a history of
lymphoproliferative disease.Screening assessment included physical examination,
laboratory measurements (including hepatitis B, C, human
immunodeficiency virus serology, polymerase chain reaction
cytomegalovirus and polymerase chain reactionEpstein-Barr
virus, interferon gamma release assay, and bhuman chorionic
gonadotropin), stool cultures (including Clostridium difficile
toxin A and B), and a chest x-ray to rule out the presence of
tuberculosis. MRI was performed at screening to evaluate the
exact anatomy and internal opening(s) of the fistula(s), their
relation to the sphincters, and the presence of abscesses. When
MRI results were nonconclusive, an examination under anes-
thesia was performed to determine the exact location of the
fistula(s). Abscesses >2 cm were surgically drained at
examination under anesthesia. Subsequently, the patient was
re-screened before proceeding to inclusion or exclusion. At
baseline, sigmoidoscopy was performed to rule out luminal
inflammation. Perianal fistulas were classified using the “simple
or complex” classification.21
All patients who did not have setons in situ after inclusion
in the study received temporary setons to ensure that the in-
ternal opening was still open at time of surgical intervention.
These setons were removed during the surgical intervention.
The study overview is shown in Supplementary Figure 1.
Patients were enrolled in a double-blind, randomized 5:2
fashion to receive locally either 1  107 (group 1), 3  107
(group 2), or 9  107 (group 3) MSCs or 0.9% NaCl/5% human
albumin solution with no cells (placebo group). Randomization
was performed at the Immunohematology and Blood Trans-
fusion Department by a researcher who did not have any
contact with or any knowledge about the included patients. The
study was posted on ClinicalTrials.gov under number
NCT01144962. Dose escalation took place after all subjects in
the previous group were treated and the Data Safety Moni-
toring Board reviewed the safety outcomes and approved study
continuation. The study was approved by the Medical Ethical
Committee of the Leiden University Medical Center (LUMC) and
the Central Committee on Research involving Human Subjects
(The Hague, Netherlands) and all patients gave written
informed consent. All data were collected in the LUMC.
Preparation of Mesenchymal Stromal Cells
MSCs were prepared from 5 different donors from 50100
mL bone marrow aspirates of healthy donors without a history
of cancer or hereditary diseases and after written informed
consent. Cells from different donors were processed separately
and MSC yield from 1 donor was sufficient to create batches of
1  107, 3  107, and 9  107 MSCs. Therefore, MSCs from 1
donor were used to treat 1 patient in each MSC group. Before
harvesting, donors underwent a medical screening, including
routine serology testing for hepatitis B, C, human immunode-
ficiency virus, syphilis, and human T-lymphotropic virus. Upon
medical indication, tuberculosis, Chagas disease, and West Nile
virus infection were ruled out. Bone marrow was collected by
aspiration from the iliac crest under local anesthesia and
mononuclear cells were subsequently isolated by Ficoll sepa-
ration techniques. Cells were then washed and resuspended in
MSC culture medium (Dulbecco’s modified Eagle’s medium
low glucose/penicillin/streptomycin/10% fetal calf serum),
plated in tissue culture flasks and incubated at 37C and 5%
CO2. MSCs were expanded according to the standardized LUMC
protocol for expansion of MSCs. Twice a week, cultures were
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ATmicroscopically examined and medium was refreshed. Cells
were trypsinized when >70% confluence was reached and MSC
half products (passage 1) of various sizes were cryopreserved
with 10% dimethyl sulfoxide. The half products were subse-
quently thawed for further expansion, enabling the use of MSC
products with similar passage numbers from all 5 donors in
each study group.
Two weeks before the intervention was planned, the patient
was randomized to receive either MSCs or placebo
(Supplementary Figure 1). When the patient was randomized to
receive MSCs, cryopreserved MSC half product was thawed,
washed, and replated in MSC culture medium for expansion to
sufficient number of cells (maximally 2 passages). MSCs were
then harvested and suspended at study groupdependent final
concentrations in 5 mL 0.9% NaCl/5% human albumin solution
divided over 2 syringes with 2.5 mL cell suspension each. This
end product was released when it met the following criteria:
>90% of the cells CD73þ/CD90þ/CD105þ, 1% of the cells
CD45þ, 0.01% of the cells CD3þ, no microbial contamination
(visual screening and BacTec culture) at 34 days before
harvest, and a final cell product with spindle-shaped cell
morphology and a colorless cell suspension appearance devoid
of cell aggregates. Viability was determined by Trypan blue
exclusion staining in a Bürker chamber. Study group
dependent final concentration of the final product was based on
the number of viable cells. Placebo consisted of 2 2.5 mL 0.9%
NaCl/5% human albumin solution.Surgical Intervention
Surgery was performed under general anaesthesia by sur-
geons with expertise in inflammatory bowel disease surgery.
Two surgeons performed the procedures. MSC or placebo im-
plantation was preceded by surgical localization of the internal
opening, removal of seton(s), curettage of the fistulous tract(s),
trimming of the mucosa and skin of the internal and external
opening, respectively, and closure of the internal opening with
a polydioxanone II 4/0 suture to diminish fecal contamination
of the fistula tract. Subsequently, the 5 mL of MSC or placebo
suspension was divided in the following 2 steps: the first sy-
ringe with 2.5 mL MSCs or placebo was injected via the anus in
the wall at 4 quadrants and equal volume around the closed
internal opening. In case of 2 internal openings, the MSCs or
placebo were divided over both closed internal openings in
equal volumes. The second volume was injected in the wall as
close as possible to the internal opening by introducing the
syringe as far as possible into the fistula tract via the external
opening. In case of more external openings, the MSCs or pla-
cebo were divided over all fistulas in equal volumes.Assessments
Safety. Follow-up visits after surgical intervention took
place at weeks 6, 12, and 24 (Supplementary Figure 1). Safety
was assessed blindly by a physician by monitoring for (serious)
adverse events and changes in vital signs at time of surgical
intervention with MSC or placebo injection at the day of
treatment and at all follow-up visits. Routine laboratory mea-
surements were performed and complications after surgery
(eg, bleeding, wound infection, and perianal abscesses) were
assessed blindly at weeks 6, 12, and 24 by a surgeon other than
the surgeon who performed the surgical intervention with MSCor placebo injection. The perianal area was examined every
study visit to assess possible detrimental effects of local in-
jections, such as abnormal tissue formation. The rectum was
also evaluated at week 12 during sigmoidoscopy. The primary
safety end point was the incidence of (serious) adverse events
at week 12. Toxicity grade of adverse events was determined
using the Common Terminology Criteria for Adverse Events
(version 3.0). Secondary end points included the incidence of
surgical intervention and infections at week 12 and 24.
Efficacy. To evaluate fistula healing, a physician assessed
blindly fistula discharge by gentle finger pressure at the
external opening. In addition, patients underwent MRI at week
12. Fistula tracts were classified blindly by a radiologist and
then compared with MRI at screening. At baseline, week 12 and
24 digital photographs were taken of the perianal area. The
primary efficacy end point at week 12 was defined as a
reduction in the number of draining fistulas determined by
absence of discharge at physical examination and absence of
collections of 2 cm directly related to the treated fistula tracts
as measured by MRI. Secondary end points included changes in
Perianal Disease Activity Index (PDAI), adapted Vaizey fecal
incontinence score, CDAI, endoscopic scores (CD Endoscopic
Index of Severity and Simplified Endoscopic Activity Score for
CD), quality of life using the Short Inflammatory Bowel Disease
Questionnaire and Short Form (SF)-36 score, and C-reactive
protein from baseline to weeks 12 and 24.Laboratory Methods for Supportive Research
Cytokine Measurements. Homogenates were pre-
pared from rectal biopsies taken at endoscopy at baseline and
week 12 (n ¼ 21), and curettage material obtained at surgical
intervention (n ¼ 20) with a Potter-Elvehjem glass homoge-
nizer at 4C in Greenberger lysis buffer (150 mM NaCl, 15 mM
Tris [pH 7.4], 1 mM MgCl2, and 1% Triton X-100). Samples
were centrifuged for 15 minutes (11,000g at 4C) and stored
at 80C. The BCA Protein Assay Kit (Thermo Scientific
Pierce, Etten-Leur, The Netherlands) was used to determine
the total concentration of protein in the samples and cytokine
levels of interleukin (IL)- 8, IL-1b, IL-6, IL-10, TNF and IL-
12p70 were measured using the Cytometric Bead Array Sys-
tem (BD Biosciences, San Diego, CA) following manufacturer’s
instructions. Data were analyzed with FlowJo software
(version 8.7.1.; TreeStar Inc, Ashland, OR). Cytokine levels
measured were corrected for the amount of total protein in
the homogenate.Statistical Analysis
In this early phase 2 study, a sample size calculation was
not performed. To compare 2 groups with numerical values,
parametric or nonparametric analyses were performed using
an unpaired Student t test or Mann-Whitney U test, respec-
tively. Paired data were compared using the unpaired t test.
Categorical data were analyzed with Fisher’s exact test. Data
were analyzed using SPSS statistical software package (2011,
version 20.0, IBM SPSS Statistics for Windows, Version 20.0.,
IBM Corp, Armonk, NY) or GraphPad Prism software (version
5.01, San Diego, CA) and expressed as means ± SEM. P  .05
was considered statistically significant.
All authors had access to the study data and have reviewed
and approved the final manuscript.





A total of 80 patients from all over the Netherlands were
referred to the LUMC to evaluate their eligibility for this
clinical trial. Of these 80 patients, 47 patients (58.8%) did
not meet the inclusion criteria and 33 patients underwent
screening, of which 12 patients did not meet the inclusion
criteria on MRI or examination under anesthesia
(Supplementary Material). Finally, 21 eligible patients were
randomized, 12 were male (57.1%) and the mean age was
38.0 years (range, 2154 years). The first patient received
intervention in June 2012, the last patient in July 2014.Table 1.Baseline Characteristics of the 21 Included Patients
Group 1 (n ¼ 5) Gr
Age, y, at inclusion
Mean (SEM) 40.4 (4.6)
Minmax 2754





Duration of CD, y
Mean (SEM) 7.6 (1.1)
Minmax 511





























AB, antibiotics; ADA, adalimumab; AZA, azathioprine; CER,
6-mercaptopurine; MTX, methotrexate; TGN, thioguanine.
aCDAI was not calculated in patients with a stoma.Additional baseline characteristics of the patients are sum-
marized in Table 1.
Mean fistula duration was 5.5 years (range, 119
years), most were complex fistulas with a trans-sphincteric
route (both 65.2%) and the internal opening was predom-
inantly observed at 6 o’clock (52.2%). The external open-
ings were mostly located at 5, 6, and 7 o’clock (all 18.8%).
A detailed overview of perianal fistula characteristics at
baseline is shown in Table 2. The primary end points were
met in all patients. For the secondary end points, 1 patient
in group 2 was not able to undergo week-12 endoscopy
and 1 patient in group 2 did not complete the week-24
questionnaires.oup 2 (n ¼ 5) Group 3 (n ¼ 5) Placebo (n ¼ 6)
40.8 (1.7) 33.4 (5.2) 37.3 (3.6)
3747 2148 2749
4 (80.0) 1 (20.0) 3 (50.0)
1 (20.0) 1 (20.0) 2 (33.3)
3 (60.0) 3 (60.0) 1 (16.7)
1 (20.0) 1 (20.0) 3 (50.0)
16.8 (4.0) 13.2 (4.1) 6.8 (2.9)
528 223 120
1 (20.0) 2 (40.0) 1 (16.7)
2 (40.0) 1 (20.0) 2 (33.3)
2 (40.0) 2 (40.0) 2 (33.3)
0 0 1 (16.7)
1 (20.0) 1 (20.0) 2 (33.3)
203.3 (51.2) 57.3 (14.1) 75.8 (28.2)
59283 3899 20148
2 (40.0) 0 0
1 (20.0) 2 (40.0) 0
2 (40.0) 4 (80.0) 4 (66.7)
2 (40.0) 1 (20.0) 2 (33.3)
0 0 0
1 (20.0) 1 (20.0) 2 (33.3)
1 (20.0) 0 1 (16.7)
2 (40.0) 2 (40.0) 2 (33.3)
1 (20.0) 1 (20.0) 1 (16.7)
3 (60.0) 3 (60.0) 5 (83.3)
3 (60.0) 1 (20.0) 0
2 (40.0) 3 (60.0) 2 (33.3)
1 (20.0) 0 0
4 (80.0) 5 (100) 4 (66.7)
3 (60.0) 2 (40.0) 2 (33.3)
1 (20.0) 0 0
1 (20.0) 1 (20.0) 0
certolizumab; CS, corticosteroids; IFX, infliximab; 6-MP,
CL
IN
Table 2.Characteristics of the Draining Perianal Fistulas in the Included Patients
Characteristics Group 1 (n ¼ 5) Group 2 (n ¼ 5) Group 3 (n ¼ 5) Placebo (n ¼ 6)
Duration of fistulas, y
Mean (SEM) 3.6 (0.7) 5.4 (2.5) 9 (3.2) 4.2 (1.1)
Minmax 25 113 219 18
PDAI at baseline
Mean (SEM) 4.4 (0.5) 3.8 (0.8) 5 (1.1) 5.2 (0.9)
Minmax 36 26 39 38
Horseshoeing, n (%)
Intralevator 1 (20.0) 2 (40.0) 1 (20.0) 4 (66.7)
Intersphincteric 1 (100) 1 (50.0) 0 2 (50.0)
Abscess, n (%)
Superficial 0 1 (50.0) 1 (100) 2 (50.0)
Supralevator 3 (60.0) 1 (20.0) 2 (40.0) 2 (33.3)
Internal openings 3 (100) 0 2 (100) 2 (100)
Internal openings, n (%) 0 1 (100) 0 0
1 5 (100) 5 (100) 5 (100) 8 (100)
2 5 (100) 5 (100) 5 (100) 4 (66.7)
Internal opening with respect to rectum, n (%) 0 0 0 2 (33.3)
Below 4 (80.0) 2 (40.0) 2 (40.0) 5 (62.5)
At 1 (20.0) 3 (60.0) 3 (60.0) 3 (37.5)
Route of fistula, n (%)
Intersphincteric 1 (20.0) 1 (20.0) 0 1 (12.5)
Trans-sphincteric 3 (60.0) 2 (40.0) 5 (100) 5 (62.5)
Suprasphincteric 1 (20.0) 0 0 0
Extrasphincteric 0 2 (40.0) 0 1 (12.5)
Superficial 0 0 0 1 (12.5)
External openings
External openings, n (%) 9 (100) 7 (100) 7 (100) 9 (100)
1 2 (40.0) 3 (60.0) 3 (60.0) 4 (66.7)
2 2 (40.0) 2 (40.0) 2 (40.0) 1 (16.7)
3 1 (20.0) 0 0 1 (16.7)
Classification fistula, n (%)21
Simple 2 (40.0) 1 (20.0) 1 (20.0) 2 (33.3)
Complex 3 (60.0) 4 (80.0) 4 (80.0) 4 (66.7)
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Six weeks after treatment, all draining fistulas had
healed in 3 of 5 (60.0%), 4 of 5 (80.0%), and 1 of 5 (20.0%)
of the patients in groups 1, 2, and 3, respectively, and in 1 of
6 (16.7%) of the patients who received placebo, as deter-
mined by absence of discharge at physical examination and
absence of 2 cm collections on MRI (P ¼ .08 group 2 vs
placebo). At week 12, all draining perianal fistulas were
healed in 2 of 5 (40.0%), 4 of 5 (80.0%), and 1 of 5 (20.0%)Figure 1. Efficacy outcomes. (A) Percentage of patients per grou
Percentage of reduction in the number of draining perianal fistula
of reduction in the number of draining perianal fistulas was signi
compared with patients in the placebo group (P ¼ .04).patients in groups 1, 2, and 3 vs 2 of 6 (33.3%) of placebo-
treated patients (Figure 1A; group 1, 2, and 3 vs placebo; all
NS). Fistula-healing rates persisted throughout week 24 in
all 3 MSC groups. In group 1, fistula healing increased to 4 of
5 (80.0%) at week 24. Analysis of all individual fistulas at
week 6 demonstrated complete healing in 4 of 9 (44.4%), 6
of 7 (85.7%), and 2 of 7 (28.6) in groups 1, 2, and 3,
respectively, vs 2 of 9 (22.2%) after treatment with placebo
(P ¼ .04 group 2 vs placebo). At week 12 after treatment,p without draining perianal fistulas at weeks 6, 12, and 24. (B)
s per group at weeks 6, 12, and 24. At week 6, the percentage
ficantly higher in patients treated with 3  107 MSCs (group 2)
Figure 2. Efficacy images.
(A) Representative digital
photos at baseline, weeks
12 and 24 of the perianal
area of 2 patients after
local treatment with 1 
107 MSCs (group 1 patient
1) or 3  107 MSCs (group
2 patient 3). In the frames,




resonance image of the
perianal area at baseline
and week 12. Patient 4 in
group 1 had 1 trans-
sphincteric fistula with
connection to the lumen at
6 o’clock with a seton in
situ (transverse image). A
superficial abscess within
the inclusion criteria was
observed at the sagittal
image. Twelve weeks after
the fistula was treated with
1  107 MSCs no fistula or
abscess was observed at
MRI.





ATcomplete fistula healing was observed in 3 of 9 (33.3%), 6 of
7 (85.7%), and 2 of 7 (28.6%) in group 1, 2 and 3 vs 3 of 9
(33.3%) in placebo (P ¼ .06 group 2 vs placebo) (Figure 1B
and illustrated in Figure 2A). At week 24, healing was
observed in 6 of 9 (66.7%), 6 of 7 (85.7%), and 2 of 7
(28.6%) in groups 1, 2, and 3, respectively, vs 3 of 9 (33.3%)
in placebo (P ¼ .06, group 2 vs placebo). The characteristics
of fistula healing in relation to MSC donor are indicated in
the Supplementary Material and Supplementary Figure 2A
and B.
MRI evaluation at week 12 revealed the presence of 2
cm collections directly related to the treated fistulas tracts
in 2 patients (1 in group 1 and 1 in the placebo group). In 2
other patients (1 in group 2 and 1 in group 3), an abscess
was formed after week 12. No de novo fistulas were
observed. At week-12 MRI, 3 patients showed no active
fistulas anymore (1 in group 1 and 2 in group 2; see
Figure 2B). Decreased amounts of fistula fluid were
observed in 2 of 5 (40.0%), 2 of 5 (40.0%), and 1 of 5
(20.0%) in groups 1, 2, and 3, respectively, vs 1 of 6 (16.7%)
in the placebo group. All patients with no or less fluid in thefistulas at the week-12 MRI also had a clinically reduction in
the number of draining fistulas.
PDAI scores at weeks 0, 12, and 24 correlated well with
therapy efficacy observed with physical examination and
MRI. In group 1, PDAI scores decreased from 4.4 to 1.8
during 24 weeks. In group 2, this PDAI decrease was most
prominent and significantly lower at week 12 compared
with baseline, as well as with placebo treatment at week 12
(P ¼ .03 group 2 from baseline to week 12; P ¼ .04 week 12
group 2 vs placebo group; Figure 3). In group 3, PDAI did
not change over time and was comparable with placebo
treatment. Effects of MSC treatment on the secondary end
points are indicated in Supplementary Tables 1 and 2.Safety
All patients tolerated the local injections of MSCs well,
no infusion reactions during or directly after the surgical
intervention occurred. One patient in group 2 developed a
fever (39.7C) 6 hours after surgery, probably related to a
stenosis dilatation of the anal canal before surgery.
Table 3.Adverse Events Reported During the Study Period of










Blood from fistula 1 — — —
Perianal swelling
Painful 1 — — 3
Not painful 1 — — 1
Abscess 1 1 1 1
Painful anal sphincters — — 1 —
Fissura ani 1 — — —
Anal blood — — — 1
Anal pus — 1 — —
Thrombosed hemorrhoid — — — 1
Pimples
Buttocks — — 1 1
Abdomen — — — 1
Activity CD
Mild 1 — — 1
Exacerbation 1 — — —
Abdominal pain 1 1 3 —
Diarrhea 1 — — 1
Flatulence — — — 1
Nausea — — 1 —
Vomiting — — 1 —
Lack of appetite 1 — — —
Pneumonia — 1 — —
Common cold 5 2 1 2
Otitis — 1 — —
Headache — 2 — —
Back pain — — 1 —
Rosacea 1 — — —
Cold sore 1 — — —
Figure 3. PDAI scores per study visit in all groups. Mean PDAI
score at week 12 was significantly decreased compared with
baseline PDAI score after treatment with 3  107 MSCs
(group 2; P ¼ .03). In addition, treatment with 3  107 MSCs
(group 2) resulted in a significantly lower PDAI score at week
12 compared with mean PDAI score in the placebo group
(P ¼ .04). Bars represent mean and SEM.
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ATHospitalization was prolonged and one dose of cefuroxime/
metronidazole was prescribed. The day after surgery, this
patient developed abdominal pain with diarrhea and
elevated C-reactive protein levels, but feces, urine, and
blood cultures were negative. No abnormalities were
observed on chest x-ray. No microbial contamination in the
supernatant of the last washing step before packaging the
MSCs for injection was found, and 2 days later the patient
was discharged in good condition.
During follow-up visits, all adverse events were recor-
ded (Table 3). All patients reported for approximately 1
week symptoms of postoperative anal pain and pus and/or
blood discharge from the fistula or anus (not shown in
Table 3). No changes in vital signs and no wound infections
or bleedings as a result of surgical intervention were
observed during the study period. In addition, no abnormal
tissue formation at the perianal area by physical examina-
tion or in the rectum at endoscopy at week 12 was found.
One patient in each group developed a perianal abscess that
required surgical drainage at weeks 12, 16, 21, and 18 in
groups 1, 2, 3, and placebo, respectively. The patients with
an abscess in groups 1, 3, and placebo needed seton
drainage. The fistula of the patient in group 2 was healed at
week 24. The 3 patients in the placebo group with a painful
perianal swelling were treated with antibiotics. None of
the adverse events were judged to be related to MSC
injection.
One of the patients treated with 1  107 MSCs developed
an adenocarcinoma of the cecum with peritoneal carcino-
matosis >15 months after the surgical intervention. Base-
line and week-12 endoscopy of the rectum revealed no
abnormalities. In addition, in retrospect, the last endoscopy
of the entire colon and the biopsies taken at that time (June
2011) were completely normal. Further evaluation revealed
that the uncle of this patient died from colon cancer at the
age of 42.Cytokine Levels in Rectal Biopsies and Fistula
Curettage Material
In order to study MSC healing mechanisms and
avoiding invasive fistula biopsies that would compromise
fistula healing, we compared rectum cytokine levels
(baseline and week 12) with fistula curettage obtained at
surgery. Mean levels of IL-8, IL-1b, and IL-6 in the rectal
biopsies were similar at baseline and after surgical inter-
vention at week 12 (Figure 4), irrespective of treatment.
No differences in the levels of these cytokines were
observed at week 12 after treatment with 1  107,
3  107, or 9  107, or placebo (data not shown), which
matched with the stable CDAI, Crohn’s Disease Endoscopic
Index of Severity, and Simplified Endoscopic Activity Score
for CD scores during the study period. Mean levels of IL-8,
IL-1b, and IL-6 were overall significantly higher in the
fistula curettage material compared with mean levels in
the rectal biopsies at either week 0 or 12 (all P < .0001).
Cytokine levels of TNF, IL-10, and IL-12p70 were below
the detection rate in all samples.Discussion
Recently, several papers have reported efficacy of local
treatment of refractory perianal fistulizing CD with
Figure 4. Cytokine levels in rectal biopsies and fistula curet-
tage material. Cytokine levels were measured in homoge-
nates of rectal biopsies and fistula curettage material. Levels
of IL-8 (A), IL-1b (B), and IL-6 (C) in the rectal biopsies ob-
tained at endoscopy were comparable at baseline and week
12. Significantly higher levels of these cytokines were
observed in the curettage material from the fistulas obtained
at surgical intervention (all, P < .0001). Bars represent mean
and SEM.





ATMSCs.1520 However, none of these trials was really
placebo-controlled. Therefore, we performed an early phase
2, double-blind, placebo-controlled, randomized study
addressing the use of allogeneic bone marrowderived
MSCs in the treatment of refractory perianal fistulizing CD.
We showed that local administration of allogeneic bone
marrowderived MSCs was safe and feasible in patients
with refractory perianal fistulizing CD.
Local treatment with lower dosages of MSCs resulted in
higher fistula healing rates compared with placebo, which
seems to be a dose-dependent response, as administration
of 3  107 MSCs resulted in high fistula healing rates and
9  107 in rates similar to placebo treatment. Previously,
the importance of MSC cell dose was described in both a
sheep model of myocardial infarction and in humans with
ischemic cardiomyopathy.22,23 In both papers, a dose esca-
lation was performed with autologous and/or allogeneic
cells that were locally injected in the diseased myocardium.
Only low-dose administration resulted in a beneficial effect
of MSCs. The authors argued that higher cell concentrations
could result in a lower survival rate and/or cell function
and, secondly, that larger number of cells could behave
immunogenic resulting in increased clearance or deactiva-
tion of the cells.
Fistula healing appeared to be accelerated after treat-
ment with 3  107 MSCs compared with placebo treatment,
as all healed fistulas in this group were already nondraining
6 weeks after the surgical intervention, as compared with at
12 weeks in patients with healed fistulas in the placebo
group. Although our fistula healing rates after treatment
with 3  107 MSCs are very encouraging, it has to be taken
into account that we only included patients in whom the
luminal CD was in remission. Local MSC treatment in pa-
tients with active luminal disease or more internal or
external openings might be less successful and therefore
merit further study. Larger phase 3 trials are warranted to
confirm our observations.Although MSC treatment was effective in groups 1 and 2,
quality of life, as measured by Short Inflammatory Bowel
Disease Questionnaire and Short Form-36, did not increase
during the study. At baseline, PDAI scores were lower than
expected for patients with perianal fistulizing CD. Both
quality of life and PDAI scores consist partially of questions
on restrictions in daily activities. All these questions were
answered in the negative, indicating that our patients did
not experience restrictions in their daily life due to the fis-
tulas, probably because, after a mean 5.5 years, they were
used to having fistulas with continuous discharge and pain,
and managed to continue with their activities despite the
daily discomfort. In addition, abscesses >2 cm were drained
before inclusion in the trial, resulting in less anal pain, lower
PDAI scores, and possibly a better quality of life.
In our study, we used allogeneic MSCs harvested from
bone marrow of healthy donors. One of the advantages of
allogeneic MSCs is the possibility of generating a stock with
“off-the-shelf” treatment potential without the requirement
to expand autologous MSCs for weeks before a patient can
be treated. Immediate availability of MSCs for the treatment
of fistulas is warranted, as development of abscesses re-
quires surgery and results in a reduced quality of life. In
addition, MSCs can be harvested from healthy young donors
with a higher yield compared with older donors and pos-
sessing a higher regenerative and immunomodulatory po-
tential also avoids possible disease-related effects on the
autologous MSCs.2426 Similar to autologous MSCs, in this
study, allogeneic MSCs were observed to be safe. During the
study period, none of the included patients reported
adverse events related to MSC injection.
One of the concerns of cell-based therapy is the safety
regarding malignant transformation of the administered
cells. Although no neoplasia were observed during the long-
term follow-up study,27 a recently published meta-analysis
14 papers28 did show occurrence of malignancies, but
only in patients with previous or current malignancies, no
formation of de novo tumors were reported. In our study,
only 1 patient (in group 1) developed an adenocarcinoma,
but it was localized in the cecum. In our patient, the rectum
was and remained completely normal at baseline and
follow-up endoscopy of the local administration site. The
local injection of MSC in this regard argues against causing
cancer at a different site. Also, the patient developed this
cancer >15 months after MSC therapy. Adult MSCs are re-
ported to have a very limited lifespan in vivo; such a late
cancer development seems incompatible with a direct
relation to MSC administration. Lastly, the patients’ uncle
died from colon cancer at age 42, suggesting a hereditary
component.
Although the recently published results on MSC treat-
ment for perianal fistulizing CD are promising, there are
substantial differences in the origin and preparation of
MSCs and techniques of administration among these studies,
making it difficult to compare.1520 We believe that an
important step to achieving MSC efficacy is the removal of
the epithelial layer present in long-standing perianal fistulas
hindering fistula healing. In addition, attention must be paid
to the closure of the internal opening because that is the
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ATplace where the fistula has emerged and prohibits fecal
contamination of the treated fistula tract. For this reason,
this was also the location of MSCs injection.
The mechanism(s) by which the administered MSCs
exert their action was not studied in our trial. MSCs possess
a broad range of immunomodulatory properties interfering
in both the innate and adaptive immune system.29,30 Pre-
and post-MSC administration, biopsies with subsequent
analysis of infiltrates could shed light whether the immu-
nosuppressive effects of MSCs in vitro can be confirmed. It
has been reported that the percentage of regulatory T cells
was increased in both rectal biopsies and peripheral blood
12 months after intrafistular MSC treatment compared with
baseline, suggesting a systemic effect of injected MSCs.18 In
our patients, active CD was only localized in the fistula with
luminal disease in remission as reflected by the stable CDAI,
Crohn’s Disease Endoscopic Index of Severity, and Simpli-
fied Endoscopic Activity Score for CD during the entire
study period. This was also reflected by the stable and low
levels of inflammatory cytokines in the biopsies. Interest-
ingly, examining the mean levels of proinflammatory cyto-
kines, IL-8, IL-1b, and IL-6, in the fistula curettage material
obtained at surgical intervention revealed baseline fistula
cytokine levels were at least significantly higher, as found in
rectal biopsies in either week 0 or 12. Unfortunately, no
follow-up material of the fistulas could be studied.
In conclusion, local administration of allogeneic bone
marrowderived MSCs was found to be safe and feasible in
patients with refractory perianal fistulizing CD. Local
treatment with 3  107 MSCs showed superior fistula
healing compared with placebo, and lower MSC dose
seemed superior to the use of a higher dose.Supplementary Material
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Supplementary Material
Patient Exclusion and Inclusion in More Detail
Forty-seven patients (58.8%) did not meet the inclusion
criteria and were therefore not screened because of the
following reasons: patient did not want to be included in the
study after oral and written information (n ¼ 13), non-
draining fistula (n ¼ 8), presence of a pouch (n ¼ 6) or a
rectovaginal fistula (n ¼ 3), fistula not proven refractory
(n ¼ 4), malignancy in the previous 5 years (n ¼ 4), no
internal opening or >2 internal openings present (both n ¼
3), no rectum in situ (n ¼ 1), heart failure (n ¼ 1), or not
willing to receive treatment for latent tuberculosis (n ¼ 1).
Twelve patients did not meet the inclusion criteria on
MRI or examination under anesthesia (EUA) at screening
because of the lack of an internal opening on MRI or EUA
(both n ¼ 3), >2 internal openings at EUA (n ¼ 1), no
external opening at baseline (n ¼ 1), or the presence of a
rectovaginal fistula at EUA or during the surgical interven-
tion (n ¼ 3 and n ¼ 1, respectively). The latter patient was
replaced.
Two patients in group 2 had a CDAI score >250 at
baseline. Both patients were included because 1 patient was
incontinent at baseline, resulting in fecal soiling approxi-
mately 20 times a day, increasing the CDAI score without
active luminal disease. The second patient had an exacer-
bation of CD at the ileocolonic anastomosis in the month
before baseline visit, but no active disease was observed
during endoscopy of the rectum and sigmoid.
More details regarding fistulas: at surgical intervention,
some patients still had an abscess related to the fistula tract,
however, those were always <2 cm. Abscesses were
drained during surgical intervention before injection of
MSCs or placebo. In the placebo group, 2 patients had a
fistula with 1 external opening that horseshoed resulting in
2 internal openings.
MSCs from 5 healthy donors were used in this trial
(Supplementary Figure 1A and B). The number of MSCs
harvested from 1 donor was sufficient to treat 1 patient in
each group. Efficacy of MSCs from donor A, C, D, and E at
week 24 was high. Five fistulas were treated with MSCs
from donor A and of these 5 fistulas 4 were nondraining at
week 24 (80%). Fistulas treated with MSCs from donor C, D,
or E were nondraining in 75.0% (3 of 4 fistulas of all
3 donors) at week 24. However, fistula healing rate after
treatment with donor B was 1 of 6 (16.7%). This might be
explained by the fact that the only 2 patients with 3 fistulas
received MSCs from donor B or placebo. In addition, injec-
tion of MSCs from donor B in patient 2 of group 3 was found
to be performed >4 hours after the MSCs were prepared
due to an emergency surgery that needed to be scheduled
before this patient. This was also the case in patient 5 of
group 2, who received MSCs from donor C.
All patients received MSCs passage 2, except for 1 pa-
tient in group 2 who received MSCs passage 3. This patient
replaced the patient who was excluded during surgical
intervention because of a rectovaginal fistula. We were able
to treat this patient with MSCs of the same donor as the
patient who was excluded, however, 1 passage extra was
needed to generate sufficient number of MSCs.
Although the sample size per group was small, making it
impossible to perform statistical tests within each group,
we analyzed the difference in the number of patients with
and without draining fistulas at week 12 and 24 based on
fistula route (Supplementary Table 3), the simple/complex
classification (Supplementary Table 4), the location of the
internal opening (Supplementary Table 5), and the number
of draining fistulas at baseline (Supplementary Table 6) in
the entire group (including placebo) with the Fisher’s exact
test in case of 2 groups with categorical data and the
Pearson’s c2 in case of >2 groups with categorical data. At
week 12 and 24 no statistically significant differences were
observed in the number of patients without draining fis-
tulas and fistula route, the simple/complex classification,
the location of the internal opening, or the number of
draining fistulas at baseline. In the subanalysis comparing
the closure rate of patients with an extrasphincteric fistula
to patients with 1 of the other 4 routes of fistulas, we did
observe a statistically significant difference between the
number of patients without draining fistulas at week 12 and
the presence of an extrasphincteric fistula at baseline (P ¼
.047). However, this difference is not significant anymore at
week 24, as the only extrasphincteric fistula in the placebo
group recurred. The extrasphincteric fistulas of the other 2
patients that were both treated with 3  107 MSCs were
still healed at week 24. Although we observed a statistically
significant difference at week 12, the number of patients
with a draining extrasphincteric fistula at baseline was too
low (n ¼ 3).
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Supplementary Figure 1. Study overview.
Supplementary Figure 2. Fistula healing in relation to MSC donor. (A) Percentage of reduction in the number of draining
perianal fistulas per MSC donor at weeks 6, 12, and 24. (B) Overview of efficacy after treatment with MSCs or placebo.
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Supplementary Table 1.Effects of Mesenchymal Stromal Cells on the Secondary End Points
Group 1 (n ¼ 5) Group 2 (n ¼ 5) Group 3 (n ¼ 5) Placebo (n ¼ 6)
CDAIa
Week 0 80.2 (12.1) 203.3 (51.2) 57.3 (14.1) 75.8 (28.2)
Week 12 76.6 (26.1) 154.8 (34.0) 74.3 (15.7) 130.3 (45.0)
Week 24b 64.8 (13.5) 171.3 (16.7) 80.8 (25.1) 58.0 (21.9)
CDEIS
Week 0 0 4.6 (4.6) 0.6 (0.6) 9.1 (5.8)
Week 12 1.2 (1.2) 0c 0.6 (0.6) 6.5 (4.8)
SES-CD
Week 0 0 1.0 (1.0) 0.2 (0.2) 2.0 (1.3)
Week 12 0.6 (0.6) 0c 0.2 (0.2) 1.8 (1.6)
Adapted Vaizey incontinence
Week 0 1.8 (0.6) 3.7 (1.9) 4.0 (1.1) 2.3 (0.3)
Week 12 0.6 (0.4) 1.0 (1.0) 3.3 (0.9) 2.0 (0.8)
Week 24b 0.8 (0.8) 1.0 (1.0) 3.0 (1.0) 1.0 (0.6)
CRP
Week 0 4.4 (2.1) 10.8 (7.1) 0 3.5 (1.7)
Week 12 5.6 (2.7) 5.2 (4.5) 1.2 (1.2) 8.9 (5.4)
Week 24b 5.7 (1.8) 7.9 (6.8) 0 4.3 (1.6)
sIBDQ
Week 0 61.0 (2.5) 48.8 (3.7) 52.8 (4.5) 55.3 (7.0)
Week 12 57.8 (4.7) 48.5 (3.8) 51.5 (4.7) 46.5 (7.2)
Week 24b 60.0 (2.7) 51.7 (1.7) 50.5 (3.4) 59.3 (3.8)
NOTE. Values are mean (SEM).
CDEIS, Crohn’s Disease Endoscopic Index of Severity; CRP, C-reactive protein; SES-CD, Simplified Endoscopic Activity
Score for Crohn’s Disease; sIBDQ, Short Inflammatory Bowel Disease Questionnaire.
aCDAI was not calculated in patients with a stoma.
bAt week 24, one patient in group 2 did not fill in the questionnaires and blood was not drawn in this patient.
cOne patient in group 2 was not able to undergo endoscopy at week 12, therefore, CDEIS and SES-CD were not calculated.
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Supplementary Table 2.Short Form-36 Scores per Group at Baseline, Week 12, and Week 24
Group 1 (n ¼ 5) Group 2 (n ¼ 5) Group 3 (n ¼ 5) Placebo (n ¼ 6)
Physical functioning
Week 0 96.0 (1.9) 75.0 (8.1) 92.0 (2.6) 85.0 (3.7)
Week 12 92.0 (4.6) 81.0 (10.8) 90.0 (4.5) 74.2 (8.9)
Week 24 97.0 (1.2) 87.5 (5.2) 92.0 (3.4) 86.7 (4.4)
Physical role functioning
Week 0 80.0 (8.2) 53.8 (14.1) 75.0 (8.1) 69.8 (9.3)
Week 12 68.8 (12.5) 61.3 (15.5) 77.5 (5.8) 56.3 (13.8)
Week 24 73.8 (9.4) 51.6 (7.8) 71.3 (5.1) 70.8 (6.8)
Bodily pain
Week 0 91.6 (5.4) 71.6 (16.5) 74.6 (9.7) 62.2 (8.3)
Week 12 82.0 (7.7) 82.8 (5.0) 89.2 (6.6) 52.7 (13.8)
Week 24 81.3 (13.9) 67.5 (3.2) 77.8 (9.8) 74.2 (8.4)
General health perceptions
Week 0 68.0 (7.3) 33.4 (8.2) 64.6 (7.0) 58.2 (10.1)
Week 12 58.2 (10.6) 32.4 (8.0) 65.0 (4.6) 47.3 (8.4)
Week 24 61.6 (8.5) 30.5 (10.8) 60.2 (4.5) 51.8 (10.1)
Vitality
Week 0 73.8 (6.7) 38.8 (7.2) 62.5 (12.5) 64.0 (5.2)
Week 12 60.0 (5.8) 45.0 (12.3) 60.0 (12.3) 50.2 (7.7)
Week 24 70.0 (7.2) 39.1 (6.4) 50.0 (13.6) 63.5 (4.4)
Social functioning
Week 0 90.0 (4.7) 57.5 (13.5) 77.5 (13.9) 87.5 (7.9)
Week 12 82.5 (5.0) 65.0 (14.5) 87.5 (12.5) 60.4 (14.9)
Week 24 82.5 (5.0) 62.5 (13.5) 80.0 (8.5) 87.5 (6.5)
Emotional role functioning
Week 0 85.0 (6.1) 51.7 (6.7) 68.3 (9.6) 80.6 (10.0)
Week 12 66.7 (11.5) 45.0 (13.1) 83.3 (10.9) 61.1 (15.2)
Week 24 80.0 (5.7) 62.5 (12.0) 71.7 (12.0) 79.2 (7.4)
Mental health
Week 0 81.0 (2.9) 51.0 (4.8) 70.0 (9.1) 79.2 (8.6)
Week 12 76.3 (6.3) 53.0 (11.0) 70.0 (6.5) 66.7 (9.3)
Week 24 85.0 (4.5) 53.8 (10.5) 66.0 (7.0) 80.0 (5.8)
NOTE. Values are mean (SEM). At week 24, one patient in group 2 did not fill in the Short Form-36.
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Supplementary Table 4.Fistula Healing Based on the Simple/Complex Classification (n ¼ 21 Patients)
Classification No draining fistulas at week 12 No draining fistulas at week 24 P value week 12 P value week 24
Simple 4/6 4/6 .331 .635
Complex 5/15 7/15
Supplementary Table 3.Fistula Healing Based on Fistula Route (n ¼ 23 Internal Openings)
Route of fistula No draining fistulas at week 12 No draining fistulas at week 24 P value week 12 P value week 24
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Supplementary Table 6.Fistula Healing Based on the Number of Draining Fistulas at Baseline (n ¼ 21 Patients)
No. of draining
fistulas at baseline No draining fistulas at week 12 No draining fistulas at week 24 P value week 12 P value week 24
1 6/12 7/12 0.417 0.296
2 3/7 4/7
3 0/2 0/2
Supplementary Table 5.Fistula Healing Based on the Location of the Internal Opening (n ¼ 23 Internal Openings)
Location internal
opening with respect
to the rectum No draining fistulas at week 12 No draining fistulas at week 24 P value week 12 P value week 24
Below 6/13 7/13 .669 1.000
At 3/10 5/10
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